Project Grant R21HL175169
Award Date
9/15/24
Completion Date
7/31/26
Dollars Obligated
$147K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Camden, NJ 08103, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will support research to determine if co-infusing the CD34+ cells with their flow-through accessory cells, normally discarded after CD34+ cell...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to advance the understanding of hematopoietic stem cell (HSC) regeneration and functionality under hypoxic (low oxygen) conditions. The total award amount is $792,498.00 over the project period from December 15, 2024, to November 30, 2028. The key objectives are to investigate how hypoxia alters gene expression and signaling related...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $299,781 to Mogling Bio Inc. to develop a therapeutic regimen that can attenuate aging of human hematopoietic stem cells (HSCs). The central goal is to validate the use of the drug CASIN to restore CDC42-regulated polarity and rejuvenate aged human HSCs ex vivo. This research aims to benefit bone marrow HSC transplant patients...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $773,257 to St. Jude Children's Research Hospital Inc. to investigate the mechanisms of lysosome segregation and cell fate regulation in dividing hematopoietic stem cells (HSCs). The research aims to identify factors regulating lysosome segregation during HSC division and how this process influences HSC self-renewal and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to expand the availability of hematopoietic stem cells (HSCs) for transplantation. The $295,438 award to the University of Florida aims to determine if the factor Netrin-1 (NTN1) can enhance the ex vivo expansion and in vivo engraftment of human HSCs, as well as support vascular function to improve hematopoietic recovery after...
This $814,209 Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to develop an innovative in vivo gene therapy approach for treating genetic blood disorders. The project aims to optimize nanoparticle formulations that can be loaded with gene-editing agents and functionalized to target hematopoietic stem cells, allowing for direct administration into the bone marrow. This approach...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will support research to identify modulators of the endoplasmic reticulum associated degradation (ERAD) pathway and evaluate their potential to enhance ex vivo expansion of hematopoietic stem cells (HSCs). The $1,458,982 award to the Regents of the University of Michigan will fund studies to determine if loss of ERAD...
This $130,337 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to characterize the cellular components of the hematopoietic stem cell (HSC) niche in the liver, identify the HSC clones that initiate liver extramedullary hematopoiesis, and investigate the role of the splicing regulator RBFOX2 in regulating liver extramedullary hematopoiesis. The research will be conducted at Columbia...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate how the protein DLK1 regulates hematopoietic stem cell (HSC) quiescence and signaling. The $680,321 award to the Fred Hutchinson Cancer Center in Seattle, WA aims to: 1) determine if DLK1 maintains and/or expands quiescent HSCs, 2) elucidate how DLK1 interactions with receptor components within cellular...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $734,607 to Boston Medical Center Corporation to conduct research on the mechanisms that regulate the migration of hematopoietic stem cells (HSCs) into their bone marrow niches. The goal is to elucidate the key endothelial cell adhesion and vesicle trafficking processes that facilitate the extravasation of HSCs, in order to...